Mainline Biosciences Secures Nearly RMB 100 Million Series A Financing to Advance Peptide-Based Innovative Drug 2.0 Pipeline

VCBeat (WeChat: vcbeat) has learned that Zhongshan Mainstream Source Biotechnology Co., Ltd. (“Mainstream Source Biotech”) recently announced the completion of its Series A financing round, raising nearly RMB 100 million. The round was led by Fuho Capital, with participation from Tanxue Capital, Dingfu Investment, and other institutions. The funds raised will be used to build the company’s core technology platform and advance clinical studies for key R&D pipelines.

Mainstream Source Biology, established in 2021, is a research-driven biotechnology company focused on the development of innovative peptide drugs 2.0. Leveraging its advanced and unique Peptide-Drug Conjugate (PDC) platform, as well as its multifunctional peptide drug screening and optimization platform, the company has developed a series of peptide drug candidates with the potential to become first-in-class new drugs. Currently, the company maintains branches in Zhongshan, Shanghai, and the United States, working together to advance the global R&D of novel peptide therapeutics.

Mainstream Source Biotech’s technology platform represents the next generation of peptide therapeutics. The company’s management team has extensive experience in cell signaling, biochemistry, structural biology, and translational medicine. By integrating computer-aided design, they continue to pioneer innovations in novel peptide drugs. The clinical development team brings years of pharmaceutical industry management expertise and has previously led the development and commercialization of blockbuster drugs such as Gleevec, Tasigna, Avastin, and Cabometyx. Leveraging computational chemistry and AI-assisted peptide design, the team can accurately simulate drug–target protein interactions, thereby enhancing druggability through appropriate peptide structural modifications. Guided by the principle of Rational Design, Mainstream Source Biotech has established a diverse pipeline. Its lead candidate, MB1707—a peptide-drug conjugate targeting CXCR4—is currently undergoing Phase I clinical trials in the United States and Australia, offering new hope for patients with CXCR4-overexpressing tumors.

Dr. Zhang Junge, Founder of Mainstream SourceStatement: We extend our sincere gratitude to Fuho Capital and all participating investment institutions for their support and recognition of our peptide-based novel drug initiatives. The team at Mainstream Source Bio will leverage our technical expertise in the field of peptide therapeutics, drive continuous innovation in Peptide-Drug Conjugates (PDCs) and multifunctional peptide drugs, and promote the development of China’s novel drug industry. This round of financing will primarily be used to advance the company’s first clinical project, develop two preclinical pipelines, and strengthen and refine our R&D team. We welcome talented individuals who share our vision to join us in building Mainstream Source into a world-class innovative peptide pharmaceutical enterprise, making positive contributions to improving human health and well-being.

Dr. Cheng Hao, Investment Partner at Fuho CapitalMainstream Source Biologics is seeking novel therapeutic strategies by building upon traditional peptide drug development, seamlessly integrating peptides with classic chemotherapeutic agents and fusing multiple peptide segments. This approach ushers in a new era of Peptide Drugs 2.0, holding significant importance for the advancement of the new drug sector. We look forward to Mainstream Source Biologics launching commercialized innovative peptide drugs that combine “efficacy, safety, and cost-effectiveness” to the global market at an early date, thereby benefiting more patients. Meanwhile, the biomedical industry in Cuiheng New Area, Zhongshan City, is committed to cultivating frontier R&D directions in biomedicine, and we anticipate the accelerated growth of Mainstream Source Biologics in this region.

Mainstream Source Biotech is a clinical-stage new drug development company. The company focuses on the field of innovative peptide therapeutics and possesses globally independent intellectual property rights for its Peptide-Drug Conjugate (PDC) and bispecific peptide drug development platforms. With extensive experience in preclinical activities—including peptide drug discovery, design, screening, and evaluation—as well as clinical development, the company aims to become a global leader in innovative peptide therapeutics.

Fuho Capital is a venture capital firm dedicated to the commercialization of scientific and technological achievements and early-stage investments in technology enterprises. It specializes in investments in healthcare, advanced manufacturing, and other sectors, with a management team possessing extensive experience in real industries and equity investment. Its healthcare portfolio includes numerous high-quality companies such as New Horizon Health (06606.HK), Airdoc Technology (02251.HK), Casecade [New Drug R&D], Zhiben Pharmaceutical [New Drug R&D], Nulan Biotech [Exosomes], Huazi Biologics [Long-acting Proteins], Baiji Hongye [New Drug R&D], Youli Medicine [New Drug R&D], Luoqi Biologics [Nanobodies], Linkcare Times [Pharmaceutical CDMO], Xinling Pharmaceutical [Transdermal Formulations], Ruishun Biologics [Cell Therapy], Respree [Inhalation Formulations], Ruiyi Technology [Pharmaceutical CDMO], Hengsai Biologics [Cell Therapy], and Zhixiang Biologics [Pharmaceutical CDMO].

Tanxue Private Equity is an equity investment institution focused on the healthcare and technology sectors, providing professional, systematic, and long-term financial services to empower companies toward lean growth and committed to jointly driving their sustained development. We are dedicated to undertaking a challenging endeavor with long-term value—creating and sharing the value of time alongside the most outstanding entrepreneurial teams. Adhering to a strategy centered on evergreen and high-growth sectors, Tanxue Private Equity leverages an industry perspective, a technology-first outlook, and long-term thinking to deeply track and nurture corporate iteration. We effectively provide multidimensional investment banking services, including upstream and downstream resource matchmaking, management expertise transfer, digital transformation tools, and tax, financial, and legal advisory.

Dingfu Investment is the industrial investment and incubation platform under the Saifu Pharmaceutical Group. By identifying opportunities at the source, empowering through its platform, and integrating resources, Dingfu continuously builds technological competitiveness for its invested projects or incubated enterprises. Dingfu has invested in well-known biotechnology companies such as Bendao Genomics and Xiji Biologics, and has successfully incubated CRO ecosystem companies including Lingfu Biologics and Renyuan Xinsheng. Founded in 2016, Saifu Pharmaceutical is committed to becoming a world-class, one-stop CRO service platform for innovative drugs. It provides comprehensive R&D planning for innovative pharmaceuticals, accelerates the drug development process, and helps enterprises achieve faster growth.